Next Weeks Broker Price Targets For Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

(NYSE:VRX) reported its EPS in the last quarter as $1.26/Share beating the analyst estimate of $1.21/Share by the difference of $0.05.

03/06/2017 - Valeant Pharmaceuticals International, Inc. had its "neutral" rating reiterated by analysts at Rodman & Renshaw.

Many analysts are providing their Estimated Earnings analysis for Valeant Pharmaceuticals International, Inc. and for the current quarter 13 analysts have projected that the stock could give an Average Earnings estimate of $0.9/share. Deutsche Bank AG set a $24.00 price objective on shares of Valeant Pharmaceuticals Intl and gave the stock a hold rating in a research note on Sunday, November 20th. On Friday, October 2 the stock rating was downgraded by Morgan Stanley to "Equal-Weight". Five equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have assigned a buy rating to the company's stock.

"Having just guided to a weaker 2017, with nothing more than "trust our commercial execution and our questionable value pipeline" to reassure investors, we worry that the timing of the refinancing suggests that (1) the organic growth in the underlying business is uncertain and could take significantly longer than expected to play out, and the company would not otherwise meet its debt repayment obligations and/or covenants over the next couple of years".

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 12.41 on Friday. The stock's 52-week range is $12.30 - $70.43. The stock's market capitalization is 4.06B. The Company's shares are trading 18.73% above their 50-day moving average and -11.37% below their 200-day moving average. Envestnet Asset Mgmt has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Adjusted net income was $1.26 per share, which topped average analysts' estimates of $1.19, according to Thomson Reuters I/B/E/S. Revenues totaled $2.40 billion for the fourth quarter of 2016, a decrease of 12.9 percent year-over-year, but above average analysts' expectations of $2.34 billion. During the same period in the prior year, the business posted $1.55 earnings per share. The business's revenue for the quarter was down 12.9% compared to the same quarter past year. If you are reading this piece on another publication, it was illegally copied and reposted in violation of global trademark and copyright legislation. The correct version of this article can be accessed at [[permalink]]. Also, Director Thomas W. Sr. The Stock now has a Weekly Volatility of 8.49% and Monthly Volatility of 5.18%. The stock's average target of $72.06 is 9.18% above today's ($66) share price. Company insiders own 16.37% of the company's stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

In other Valeant Pharmaceuticals Intl news, Director Pershing Square Capital Manage sold 3,476,690 shares of the firm's stock in a transaction on Monday, December 12th. The disclosure for this sale can be found here. EQT Midstream Partners, LP (EQM), an EQT Corporation company, declared that its 2016 unitholder tax packages are available online.

Several hedge funds and other institutional investors have recently bought and sold shares of VRX. Davis Selected Advisers now owns 7,304,762 shares of the specialty pharmaceutical company's stock valued at $147,118,000 after buying an additional 64,425 shares during the period. WFG Advisors LP increased its stake in Valeant Pharmaceuticals Intl by 302.5% in the fourth quarter. Cap Fund Mngmt Sa invested in 36,494 shares. Frontier Wealth Management LLC purchased a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth approximately $149,000. Legal & General Group Plc now owns 1,231,930 shares of the specialty pharmaceutical company's stock worth $24,710,000 after buying an additional 22,793 shares in the last quarter.

Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its earnings results on Tuesday, February 28th. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International, Inc. with's FREE daily email newsletter.

Shares of Valeant Pharmaceuticals International, Inc.

  • Joanne Flowers